Literature DB >> 18210112

[Molecular pathology analysis of the KRAS mutation status in patients with metastasized colorectal carcinoma: an initial approach using predictive pathology].

A Tannapfel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18210112     DOI： 10.1007/s00292-007-0966-y

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


× No keyword cloud information.
  3 in total

Review 1.  The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

Authors:  Josep Tabernero
Journal:  Mol Cancer Res       Date:  2007-03       Impact factor: 5.852

2.  KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

Authors:  W De Roock; H Piessevaux; J De Schutter; M Janssens; G De Hertogh; N Personeni; B Biesmans; J-L Van Laethem; M Peeters; Y Humblet; E Van Cutsem; S Tejpar
Journal:  Ann Oncol       Date:  2007-11-12       Impact factor: 32.976

3.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Marc Peeters; Salvatore Siena; Yves Humblet; Alain Hendlisz; Bart Neyns; Jean-Luc Canon; Jean-Luc Van Laethem; Joan Maurel; Gary Richardson; Michael Wolf; Rafael G Amado
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544
  3 in total
  1 in total

1.  KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.

Authors:  Wilko Weichert; Christiane Schewe; Annika Lehmann; Christine Sers; Carsten Denkert; Jan Budczies; Albrecht Stenzinger; Hans Joos; Olfert Landt; Volker Heiser; Christoph Röcken; Manfred Dietel
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.